{
  "source": "PA-Notification-Jynarque.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 1251-7\nProgram Prior Authorization/Notification\nMedication Jynarque® (tolvaptan)\nP&T Approval Date 8/2018, 8/2019, 8/2020, 8/2021, 8/2022, 8/2023, 8/2024\nEffective Date 11/1/2024\n1. Background:\nJynarque is a selective vasopressin V2-receptor antagonist indicated to slow\nkidney function decline in adults at risk of rapidly progressing autosomal dominant\npolycystic kidney disease (ADPKD).\n2. Coverage Criteriaa:\nA. Autosomal Dominant Polycystic Kidney Disease\n1. Initial Authorization\na. Jynarque will be approved based on of the following criterion:\n(1) Diagnosis of autosomal dominant polycystic kidney disease (ADPKD)\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Jynarque will be approved based on the following criterion:\n(1) Documentation of positive clinical response to Jynarque therapy\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Supply limits may be in place.\n© 2024 UnitedHealthcare Services, Inc.\n1\n4. References:\n1. Jynarque [package insert]. Rockville MD: Otsuka America Pharmaceutical, Inc.; October\n2020.\nProgram Prior Authorization/Notification – Jynarque (tolvaptan)\nChange Control\n8/2018 New program.\n8/2019 Annual review with no changes to coverage criteria.\n8/2020 Annual review with no changes to coverage criteria.\n8/2021 Annual review with no changes to coverage criteria. Updated\nreference.\n8/2022 Annual review with no changes to coverage criteria. Ad",
    ".\n8/2020 Annual review with no changes to coverage criteria.\n8/2021 Annual review with no changes to coverage criteria. Updated\nreference.\n8/2022 Annual review with no changes to coverage criteria. Added state\nmandate footnote.\n8/2023 Annual review with no changes to coverage criteria.\n8/2024 Annual review with no changes to coverage criteria.\n© 2024 UnitedHealthcare Services, Inc.\n2"
  ]
}